Abstract
Background and objectives: Emergence and spread of antibiotic resistance among bacteria pose a challenge to clinicians due to limited therapeutic options available. Multi drug resistant (MDR) bacteria are known to cause life threatening infections in intensive care settings. Tigecycline is a newer glycycline antibiotic, considered as therapeutic option for MDR gram positive and gram negative bacteria. Aim of this study was to evaluate in-vitro susceptibility of tigecycline in MDR bacteria. Methods : We studied the in-vitro activity of tigecycline in 100 MDR bacteria isolated from blood, skin, soft tissue and surgical site infections, urine, sputum, bronchoalveolar lavage, CSF and other body fluids of patients admitted to a tertiary care hospital in South India. MDR bacteria tested for tigecycline susceptibility by disc diffusion and E-test included: Methicillin resistant S.aureus (MRSA) (35), extended spectrum β lactamase (ESBL) producing Enterobacteriaceae (36), P.aeruginosa (15) and Acinetobacter spp . (14). Results: Tigecycline was found effective against all isolates of MRSA (MIC90 0.25
Highlights
Due to the emergence and spread of multidrug resistant (MDR) pathogens in health care settings clinicians are facing an acute shortage of antibiotics with broad spectrum activity that can be suitably used in initial empiric therapy[1]
Interpretation & conclusions: This study shows that tigecycline can be a useful reserve antibiotic against Multi drug resistant (MDR) Methicillin resistant S.aureus (MRSA) and ESBL producing Enterobacteriaceae, but a higher prevalence of resistance is seen among members of Acinetobacter spp and P.aeruginosa
Tigecycline has emerged as an useful alternative antibiotic in the treatment of intraabdominal and skin and soft tissue infections caused by MDR gram negative bacilli and MRSA
Summary
Due to the emergence and spread of multidrug resistant (MDR) pathogens in health care settings clinicians are facing an acute shortage of antibiotics with broad spectrum activity that can be suitably used in initial empiric therapy[1]. Interpretation & conclusions: This study shows that tigecycline can be a useful reserve antibiotic against MDR MRSA and ESBL producing Enterobacteriaceae, but a higher prevalence of resistance is seen among members of Acinetobacter spp and P.aeruginosa. Carbapenems were considered to be antibiotic of choice in the treatment of life threatening infections caused by MDR Enterobacteriaceae and non-fermenters such as P.aeruginosa and Acinetobacter spps..
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
